FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Zyprexa, olanzapine, is an antipsychotic medicine.
Estonian: Zyprexa toimeaine olansapiin on antipsühhootikum (psühhoosivastane ravim).
English: Their effectiveness was compared with that of placebo or lithium (another medicine used in bipolar disorder).
Estonian: Nende efektiivsust võrreldi platseebo või liitiumi (samuti bipolaarse meeleoluhäire ravim) efektiivsusega.
English: What is the risk associated with Zyprexa?
Estonian: Mis riskid Zyprexaga kaasnevad?
English: For the full list of all side effects reported with Zyprexa, see the package leaflet.
Estonian: Zyprexa kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The injection was also shown to be more effective than lorazepam (at a relatively low dose) in manic patients, and as effective as haloperidol in schizophrenia.
Estonian: Ka ravimi süstimine osutus maaniapatsientidel efektiivsemaks kui lorasepaam (suhteliselt väikeses annuses) ja skisofreeniapatsientidel sama efektiivseks kui haloperidool.
English: The recommended starting dose of Zyprexa tablets depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Estonian: Zyprexa tablettide soovituslik algannus sõltub ravitavast haigusest: skisofreenia korral ja maaniaepisoodide ennetamiseks kasutatakse annust 10 mg ööpäevas ning maaniaepisoodide raviks
English: In the treatment of acute manic episodes in adults with bipolar disorder, Zyprexa tablets were compared with placebo, haloperidol or valproate (another medicine used in manic episodes) in five studies, including one where patients were also receiving other medicines.
Estonian: Zyprexa tablettide kasutamist ägedate maaniaepisoodide raviks bipolaarse meeleoluhäirega täiskasvanud patsientidel võrreldi platseebo, haloperidooli või valproaadi kasutamisega (samuti maaniaepisoodide ravim) viies uuringus, kusjuures ühes neist said patsiendid ka muid ravimeid.
English: In schizophrenia, Zyprexa tablets have been studied in about 3,000 adults, in which their effectiveness was compared with that of placebo (a dummy treatment) or haloperidol (another antipsychotic medicine).
Estonian: Zyprexa tablettide kasutamist skisofreenia korral uuriti ligikaudu 3000 täiskasvanud patsiendil, kellel võrreldi Zyprexa tablettide efektiivsust platseebo (näiva ravimi) või haloperidooli (samuti antipsühhootikumi) efektiivsusega.
English: How does Zyprexa work?
Estonian: Kuidas Zyprexa toimib?
English: What benefit has Zyprexa shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zyprexa kasulikkus?
English: What is Zyprexa used for?
Estonian: Milleks Zyprexat kasutatakse?
English: How has Zyprexa been studied?
Estonian: Kuidas Zyprexat uuriti?
English: How is Zyprexa used?
Estonian: Kuidas Zyprexat kasutatakse?
English: Zyprexa tablets were at least as effective as the medicines they were compared with for the treatment of schizophrenia (haloperidol), the treatment of moderate to severe manic episodes
Estonian: Zyprexa tabletid olid vähemalt sama efektiivsed kui võrdlusravimid skisofreenia ravimisel (haloperidool), mõõdukate ja raskete maaniaepisoodide ravimisel (haloperidool ja valproaat) ning taastekke ennetamiseks bipolaarse meeleoluhäirega patsientidel (liitium).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Sprimeo HCT on 23 June 2011.
Estonian: Euroopa Komisjon andis Sprimeo HCT müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 23. juunil 2011.
English: The full EPAR for Sprimeo HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Sprimeo HCT kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Overall, the company presented the results of nine main studies involving a total of almost 9,000 patients with essential hypertension.
Estonian: Kokku esitas ettevõtte ligikaudu 9000 essentsiaalse hüpertensiooniga patsienti hõlmanud 9 põhiuuringu tulemused.
English: The most common side effect with Sprimeo HCT (seen in between 1 and 10 patients in 100) is diarrhoea.
Estonian: Sprimeo HCT kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on kõhulahtisus.
English: This authorisation was based on the authorisation of Rasilez HCT in 2009 (‘informed consent').
Estonian: Müügiluba põhineb ravimi 2009. aastal antud Rasilez HCT müügiloal (teabel põhinev nõusolek).
English: The CHMP decided that Sprimeo HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Sprimeo HCT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The recommended dose of Sprimeo HCT is one tablet per day.
Estonian: Sprimeo HCT soovitatav annus on üks tablett ööpäevas.
English: Three additional studies were carried out to show that the active substances were absorbed in the body in the same way when they taken as separate tablets and as Sprimeo HCT.
Estonian: Tehti ka kolm lisauuringut eesmärgiga näidata, et toimeained imendusid organismis ühesugusel viisil, olenemata sellest, kas need võeti eraldi tablettide või Sprimeo HCT-na.
English: For more information about treatment with Sprimeo HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Sprimeo HCT-ga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Sprimeo HCT.
Estonian: See on ravimi Sprimeo HCT Euroopa avaliku hindamisaruande kokkuvõte.
English: For the full list of all side effects reported with Sprimeo HCT, see the package leaflet.
Estonian: Sprimeo HCT kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Other information about Sprimeo HCT
Estonian: Muu teave Sprimeo HCT kohta
English: The company presented information used in the assessment of aliskiren and from the published literature to support its application for Sprimeo HCT, as well as information from additional studies.
Estonian: Ettevõte esitas Sprimeo HCT müügiloa taotluse toetuseks teabe, mida kasutati aliskireeni hindamiseks, samuti kirjanduses avaldatud ning lisauuringutest saadud teabe.
English: Patients previously taking only aliskiren or hydrochlorothiazide may need to take the two substances as separate tablets and adjust the doses before switching to Sprimeo HCT.
Estonian: Patsientidel, kes varem said üksnes aliskireeni või hüdroklorotiasiidi, võib olla vaja võtta kumbagi toimeainet eraldi tablettidena ja kohandada annuseid, enne kui nad lähevad üle Sprimeo HCT võtmisele.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sprimeo HCT.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Sprimeo HCT was more effective than placebo in reducing blood pressure.
Estonian: Sprimeo HCT vähendas vererõhku efektiivsemalt kui platseebo.
English: Sprimeo HCT is used in patients whose blood pressure is not adequately controlled by aliskiren or hydrochlorothiazide taken alone.
Estonian: Sprimeo HCT-d kasutatakse patsientidel, kelle vererõhk ei allu üksnes aliskireeni või hüdroklorotiasiidiga piisavalt ravile.
English: Sprimeo HCT contains two active substances, aliskiren and hydrochlorothiazide.
Estonian: Sprimeo HCT sisaldab kaht toimeainet, aliskireeni ja hüdroklorotiasiidi.
English: Sprimeo HCT is a medicine that contains the active substances aliskiren and hydrochlorothiazide.
Estonian: Sprimeo HCT on ravim, mis sisaldab toimeainetena aliskireeni ja hüdroklorotiasiidi.
English: In patients whose blood pressure was not adequately controlled on either aliskiren or hydrochlorothiazide alone, switching to the combination resulted in greater falls in blood pressure than remaining on one active substance alone.
Estonian: Patsientidel, kelle vererõhk ei allunud piisavalt ravile üksnes aliskireeni või hüdroklorotiasiidiga, langes kahe toimeaine kombinatsioonile ülemineku tulemusena vererõhk rohkem kui ravi jätkamisel ainult ühe toimeainega.
English: It works by increasing urine output, reducing the amount of fluid in the blood and reducing blood pressure.
Estonian: See suurendab uriinieritust ning vähendab vedeliku hulka veres, mille tulemusena vererõhk langeb.
English: Sprimeo HCT is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Sprimeo HCT-d kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanud patsientidel.
English: It can also be used in patients whose blood pressure is adequately controlled with aliskiren and hydrochlorothiazide taken as separate tablets, to replace the same doses of the two active substances.
Estonian: Ravimit tohib kasutada ka patsientidel, kelle vererõhk allub piisavalt ravile aliskireeni ja hüdroklorotiasiidiga eraldi võetud tablettidena, et asendada kaks tabletti ühega, mis sisaldab kaht toimeainet samas annuses.
English: It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Sprimeo
Estonian: Seda manustatakse koos kerge einega, eelistatavalt iga päev samal kellaajal.
English: Why has Sprimeo HCT been approved?
Estonian: Miks Sprimeo HCT heaks kiideti?
English: Sprimeo HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Sprimeo HCT-d ei tohi kasutada koos angiotensiini muundava ensüümi (ACE) inhibiitorite ega angiotensiini retseptori blokaatoritega (ARB), kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: What is Sprimeo HCT?
Estonian: Mis on Sprimeo HCT?
English: Sprimeo HCT must not be used in people who are hypersensitive (allergic) to aliskiren, hydrochlorothiazide, any of the other ingredients or sulfonamides.
Estonian: Sprimeo HCT-d ei tohi kasutada patsiendid, kes on aliskireeni, hüdroklorotiasiidi või selle ravimi mis tahes muu koostisaine või sulfoonamiidide suhtes ülitundlikud (allergilised).
English: In patients already adequately controlled with the two active substances, the dose of Sprimeo HCT must contain the same doses of aliskiren and hydrochlorothiazide that the patient was taking before.
Estonian: Kui patsiendi vererõhk allub mõlemale toimeainele piisavalt, peab Sprimeo HCT sisaldama aliskireeni ja hüdroklorotiasiidi annuses, mida patsient varem võttis.
English: It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Estonian: Aliskireen on reniini inhibiitor, mis blokeerib organismis angiotensiin I tekkes osaleva inimensüümi reniini toime.
English: What is the risk associated with Sprimeo HCT?
Estonian: Mis riskid Sprimeo HCT-ga kaasnevad?
English: It must not be taken with ciclosporin, itraconazole, or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Estonian: Sprimeo HCT-d ei tohi manustada koos tsüklosporiini, itrakonasooli ega teiste ravimitega, mis on tugevad P-gp inhibiitorid (nt kinidiin).
English: After two to four weeks of taking Sprimeo HCT, the dose can be increased in patients whose blood pressure remains uncontrolled.
Estonian: Patsientidel, kelle vererõhk ei allu ravile Sprimeo HCT-ga kahe kuni nelja nädala jooksul, tohib annust suurendada.
English: What benefit has Sprimeo HCT shown during the studies?
Estonian: Milles seisneb uuringute põhjal Sprimeo HCT kasulikkus?
English: How does Sprimeo HCT work?
Estonian: Kuidas Sprimeo HCT toimib?
English: How is Sprimeo HCT used?
Estonian: Kuidas Sprimeo HCT-d kasutatakse?
English: What is Sprimeo HCT used for?
Estonian: Milleks Sprimeo HCT-d kasutatakse?
English: How has Sprimeo HCT been studied?
Estonian: Kuidas Sprimeo HCT-d uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Sprimeo HCT on retseptiravim.
English: Elonva received a marketing authorisation valid throughout the European Union on 25 January 2010.
Estonian: Elonva on saanud müügiloa, mis kehtib kogu ELis, 25. jaanuaril 2010.
English: What measures are being taken to ensure the safe and effective use of Elonva?
Estonian: Mis meetmed võetakse, et tagada Elonva ohutu ja efektiivne kasutamine?
English: Further information on Elonva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/elonva.
Estonian: Lisateave Elonva kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/elonva.
English: Both these studies involved women aged 18 to 36 years.
Estonian: Mõlemas uuringus osalesid 1836-aastased naised.
English: They will then be fertilised in a laboratory and the resulting embryo is implanted in the womb.
Estonian: Seejärel viljastatakse need laboris ja saadud embrüo implanteeritakse emakasse.
English: The European Medicines Agency decided that Elonva's benefits are greater than its risks and it can be authorised for use in the EU..
Estonian: Euroopa Ravimiamet otsustas, et Elonva kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: The eggs are collected using a surgical procedure.
Estonian: Munarakud kogutakse kirurgilise protseduuriga.
English: Why is Elonva authorised in the EU?
Estonian: Miks Elonva ELis heaks kiideti?
English: Other information about Elonva
Estonian: Muu teave Elonva kohta
English: What is Elonvaand what is it used for?
Estonian: Mis on Elonva ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Elonva are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Elonva kasutamise kohta pidevat järelevalvet.
English: What are the risks associated with Elonva?
Estonian: Mis riskid Elonvaga kaasnevad?
English: Side effects reported with Elonva are carefully evaluated and any necessary action taken to protect patients.
Estonian: Elonva kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Elonva (corifollitropin alfa)
Estonian: Elonva (alfakorifollitropiin)
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elonva have been included in the summary of product characteristics and the package leaflet.
Estonian: Elonva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Elonva, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Elonva kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Four or five days after the Elonva injection, depending on how the ovaries have responded, treatment is started with a GnRH antagonist, which prevents the ovaries from releasing their eggs too early.
Estonian: 4-5 päeva pärast Elonva manustamist, sõltuvalt sellest, kuidas munasarjad on ravimile reageerinud, alustatakse ravi GnRH-antagonistiga, mis takistab munarakkude liiga varast vabanemist munasarjadest.
English: In three main studies involving 3,292 women who needed to have ovarian stimulation, Elonva treatment has been shown to be as effective as treatment with follitropin beta (an FSH medicine also used to stimulate the ovaries).
Estonian: Kolmes põhiuuringus, milles osales 3292 munasarjade stimuleerimist vajavat naist, tõendati, et ravi Elonvaga oli sama efektiivne kui ravi beetafollitropiiniga (samuti munasarjade stimuleerimise FSH-ravim).
English: The main measure of effectiveness for these studies was the average number of eggs collected from each woman after treatment.
Estonian: Efektiivsuse põhinäitaja oli mõlemas uuringus igalt naiselt pärast ravi kogutud munarakkude keskmine arv.
English: Elonva can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating fertility problems.
Estonian: Elonva on retseptiravim ning ravi tohib alustada ainult viljakusprobleemide ravis kogenud arsti järelevalve all.
English: FSH stimulates the production of eggs in the ovaries.
Estonian: FSH stimuleerib munarakkude teket munasarjades.
English: It is given once as a single injection under the skin in a dose of 100 or 150 micrograms, depending on age and body weight.
Estonian: Elonvat manustatakse ühekordse subkuntaanse süstina annuses 100 või 150 µg, olenevalt patsiendi vanusest ja kehamassist.
English: It must also not be used in women with abnormal (not menstrual) bleeding from the vagina without a known cause, fibroids or malformations of the womb that would prevent pregnancy, primary ovarian failure, enlarged ovaries or ovaries with cysts, or in women with risk factors for OHSS such as polycystic ovarian syndrome.
Estonian: Hüpofüüs ehk ajuripats on ajupõhimikul asuv nääre, mis toodab FSH-d. Elonvat ei tohi kasutada ka naised, kellel on teadmata põhjusega ebanormaalne vaginaalne veritsus (v.a menstruaalne), emaka fibroidid või malformatsioonid, mis võivad takistada rasestumist, primaarne munasarjapuudulikkus, suurenenud või tsüstilised munasarjad, või naised, kellel on munasarjade hüperstimulatsiooni sündroomi risk, nt polütsüstiliste munasarjade sündroom.
English: Elonva is a hormonal medicine used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
Estonian: Elonva on hormoonravim, mida kasutatakse viljakusravi saavatel naistel, et stimuleerida korraga mitme munaraku küpsemist munasarjades.
English: Finally, as soon as three eggs are close to maturation, a single injection of a hormone called human chorionic gonadotropin (hCG) is given to release the mature eggs.
Estonian: Kui kolm munarakku on peaaegu küpsed, manustatakse ühekordne annus hormooni inimese kooriongonadotropiini (hCG), mis vabastab küpsed munarakud munasarjadest.
English: As a result, a single dose of the medicine can be given to stimulate egg production for seven days, instead of daily injections that would be required with other FSH medicines.
Estonian: Selle tulemusena saab Elonvat munarakkude tekke stimuleerimiseks manustada ühe annusena 7 päeva kohta, erinevalt muudest FSH-d sisaldavatest ravimitest, mida tuleb süstida iga päev.
English: How does Elonva work?
Estonian: Kuidas Elonva toimib?
English: The most common side effects with Elonva (which may affect up to 1 in 10 people) are headache, nausea (feeling sick), tiredness, pelvic pain and discomfort, breast tenderness and ovarian hyperstimulation syndrome (OHSS).
Estonian: Elonva kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, iiveldus, väsimus, valu ja ebamugavustunne vaagnapiirkonnas, rindade tundlikkus ning munasarjade hüperstimulatsiooni sündroom.
English: Elonva contains the active substance corifollitropin alfa.
Estonian: Elonva sisaldab toimeainena alfakorifollitropiini.
English: The study in women over 60 kg had an additional main effectiveness measure which was the number of women with a successful early pregnancy.
Estonian: Üle 60 kg kaaluvate naiste uuringus kasutati ka teist efektiivsuse põhinäitajat - rasestunud naiste arv.
English: What benefits of Elonva have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Elonva kasulikkus?
English: OHSS occurs when the ovaries over-respond to treatment, causing abdominal swelling and pain, nausea and diarrhoea.
Estonian: Munasarjade hüperstimulatsiooni sündroom tekib, kui munasarjad reageerivad ravile liiga tugevasti, mis põhjustab turset ja valu kõhupiirkonnas, iiveldust ja kõhulahtisust.
English: It is used together with a gonadotrophin-releasing hormone (GnRH) antagonist (another type of medicine used in fertility treatments).
Estonian: Elonvat kasutatakse koos gonadotropiini vabastava hormooni (GnRH) antagonistiga (samuti viljakusravim).
English: Around 39% of those who received Elonva became pregnant compared with 38% of those treated with follitropin beta.
Estonian: Elonvat saanud naistest rasestus ligikaudu 39% ja beetafollitropiini saanutest 38%.
English: For the full list of side effects of Elonva, see the package leaflet.
Estonian: Elonva kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Elonva used?
Estonian: Kuidas Elonvat kasutatakse?
English: One of the studies involved women weighing 60 kg or less who received a 100-microgram dose of Elonva, and a second study involved women weighing above 60 kg who received a 150-microgram dose.
Estonian: Ühes uuringus osalesid kuni 60 kg kaaluvad naised, kellele manustati Elonvat annuses 100 µg, teises üle 60 kg kaaluvad naised, kellele manustati Elonvat annuses 150 µg.
English: The active substance in Elonva, corifollitropin alfa, is similar to follicle stimulating hormone (FSH), a natural hormone in the body.
Estonian: Elonva toimeaine alfakorifollitropiin sarnaneb organismis looduslikult tekkivale folliikuleid stimuleerivale hormoonile (FSH).
English: Seven days after the Elonva injection, if further ovarian stimulation is needed, injections of another medicine similar to Elonva, but suitable for daily injection, may be given.
Estonian: Kui on vaja täiendavat munasarjade stimuleerimist, tohib 7 päeva pärast Elonva manustamist süstida teist ravimit, mille toime sarnaneb Elonva toimega, kuid mida võib manustada iga päev.
English: In corifollitropin alfa, a peptide (a short chain of amino acids) is attached to the FSH to prolong its activity in the body.
Estonian: Alfakorifollitropiin erineb FSH-st selle poolest, et alfakorifollitropiinile on toime pikendamiseks organismis lisatud teatud peptiid (lühike aminohapete ahel).
English: In the second study in women weighing above 60 kg, the average number of eggs collected from each woman was 13.8 in those treated with Elonva compared with 12.6 in those treated with follitropin beta.
Estonian: Teises, üle 60 kg kaaluvate naiste uuringus oli igalt naiselt pärast ravi kogutud munarakkude keskmine arv Elonva uuringurühmas 13,8 ja beetafollitropiini uuringurühmas 12,6.
English: An overview of Elonva and why it is authorised in the EU
Estonian: Ülevaade ravimist Elonva ja ELis müügiloa väljastamise põhjendus
English: In the first study in women weighing 60 kg or less, the number of eggs collected from each woman was 13.3 for those treated with Elonva and 10.6 for those treated with follitropin beta.
Estonian: Esimeses, kuni 60 kg kaaluvate naiste uuringus oli igalt naiselt pärast ravi kogutud munarakkude keskmine arv Elonva uuringurühmas 13,3 ja beetafollitropiini uuringurühmas 10,6.
English: The third study involved women in the age range 35 to 42 years weighing 50 kg or more who were given a 150-microgram dose of Elonva; the main measure of effectiveness in this study was the number of women with a successful early pregnancy, and 24 and 27% of women treated with Elonva and follitropin beta respectively became pregnant.
Estonian: Efektiivsuse põhinäitaja oli selles uuringus rasestunud naiste arv: Elonva või follitropiiniga ravitud naistest rasestus vastavalt 24% ja 27%.
English: Elonva must not be used in patients with tumours of the ovary, breast, womb, pituitary (a gland located at the base of the brain that produces FSH) or hypothalamus (a region of the brain).
Estonian: Elonvat ei tohi kasutada patsiendid, kellel on munasarja-, rinna-, emaka-, hüpofüüsi- või hüpotalamusekasvaja.
English: Elonva is available as a solution for injection.
Estonian: Elonvat turustatakse süstelahusena.